Jointown Pharmaceutical Group Co., Ltd (SHA:600998)

SHA:600998 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	155,621	151,695	149,981	140,282	122,359	110,819
Other Revenue	124.14	115.13	158.54	142.16	48.09	40.49
Revenue	155,745	151,810	150,140	140,424	122,407	110,860
Revenue Growth (YoY)	5.27%	1.11%	6.92%	14.72%	10.42%	11.42%
Cost of Revenue	144,043	140,075	138,140	129,560	112,636	100,981
Gross Profit	11,702	11,735	12,000	10,864	9,772	9,879
Selling, General & Admin	7,524	7,229	7,193	6,637	6,097	5,667
Research & Development	146.65	146.7	196.61	178.39	194.94	126.63
Other Operating Expenses	477.96	413.12	425.65	98.16	293.01	253.25
Operating Expenses	8,354	7,813	7,947	7,074	6,684	6,155
Operating Income	3,348	3,923	4,053	3,790	3,087	3,724
Interest Expense	-1,139	-1,284	-1,318	-1,221	-1,145	-1,027
Interest & Investment Income	2,264	1,456	255.17	490.63	310.74	288.54
Currency Exchange Gain (Loss)	-14.19	-0.81	-4.34	-17.05	-6.65	-1.53
Other Non Operating Income (Expenses)	-85.74	-138.58	-265.43	-281.66	-151.72	-155.5
EBT Excluding Unusual Items	4,373	3,955	2,721	2,760	2,094	2,828
Impairment of Goodwill	-10.85	-10.85	-1.18	-	-	-
Gain (Loss) on Sale of Investments	-6.37	-98.35	-78.4	1.44	1,235	1,052
Gain (Loss) on Sale of Assets	-668.14	-425.83	5.11	45.67	6.72	258.03
Asset Writedown	-	-	-	-	-2.35	-0.69
Other Unusual Items	286.1	217.45	344.62	30.9	29.12	196.12
Pretax Income	3,974	3,637	2,991	2,838	3,363	4,334
Income Tax Expense	919.09	851.03	701.2	552.55	754.88	948.94
Earnings From Continuing Operations	3,055	2,786	2,290	2,286	2,608	3,385
Minority Interest in Earnings	-309.37	-279.05	-115.62	-200.57	-160.05	-310.03
Net Income	2,745	2,507	2,174	2,085	2,448	3,075
Net Income to Common	2,745	2,507	2,174	2,085	2,448	3,075
Net Income Growth	34.66%	15.33%	4.27%	-14.84%	-20.38%	78.10%
Shares Outstanding (Basic)	5,092	5,015	5,056	5,274	5,187	5,172
Shares Outstanding (Diluted)	5,092	5,015	5,056	5,274	5,187	5,339
Shares Change (YoY)	4.16%	-0.81%	-4.14%	1.68%	-2.84%	-3.46%
EPS (Basic)	0.54	0.50	0.43	0.40	0.47	0.59
EPS (Diluted)	0.54	0.50	0.43	0.40	0.47	0.58
EPS Growth	29.28%	16.28%	8.78%	-16.25%	-18.06%	84.50%
Free Cash Flow	2,135	2,107	3,699	2,743	2,073	1,987
Free Cash Flow Per Share	0.42	0.42	0.73	0.52	0.40	0.37
Dividend Per Share	0.200	0.200	0.194	0.186	0.112	0.186
Dividend Growth	3.20%	3.20%	4.31%	66.64%	-39.99%	-
Gross Margin	7.51%	7.73%	7.99%	7.74%	7.98%	8.91%
Operating Margin	2.15%	2.58%	2.70%	2.70%	2.52%	3.36%
Profit Margin	1.76%	1.65%	1.45%	1.49%	2.00%	2.77%
Free Cash Flow Margin	1.37%	1.39%	2.46%	1.95%	1.69%	1.79%
EBITDA	4,016	4,612	4,730	4,416	3,634	4,239
EBITDA Margin	2.58%	3.04%	3.15%	3.15%	2.97%	3.82%
D&A For EBITDA	668.11	689.68	676.96	626.41	547.21	514.33
EBIT	3,348	3,923	4,053	3,790	3,087	3,724
EBIT Margin	2.15%	2.58%	2.70%	2.70%	2.52%	3.36%
Effective Tax Rate	23.13%	23.40%	23.45%	19.47%	22.45%	21.89%
Revenue as Reported	155,745	151,810	150,140	140,424	122,407	110,860

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.